Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Durvalumab (MEDI4736), in Subjects With Relapsed or Refractory Solid Tumors

NCT02403271 is registered in ClinicalTrials.gov with Pharmacyclics LLC. as lead sponsor.

NCT NCT02403271
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02403271 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Durvalumab (MEDI4736), in Subjects With Relapsed or Refractory Solid Tumors
Lead sponsor
Pharmacyclics LLC.
Phase
Phase 1/2
Overall status
Completed
Start date
March 31, 2015
Completion date
August 31, 2017
Enrollment
124 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, non-small cell lung cancer, pancreatic cancer